Warfarin-induced hypoprothrombinemia. Potentiation by hyperthyroidism.
D000284:Administration, Oral; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D002536:Cerebral Arteries; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications*; D007020:Hypoprothrombinemias / Q000139:chemically induced* / Q000209:etiology; D007275:Injections, Intravenous; D008875:Middle Aged; D011441:Propylthiouracil / Q000627:therapeutic use; D011517:Prothrombin Time; D012964:Sodium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013958:Thyroid Crisis / Q000150:complications; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D014859:Warfarin; D011441:Propylthiouracil; D006493:Heparin; D012964:Sodium